![COVID-19 vs. community oncology: Flatiron's data provides first damage assessment](https://cdn.cancerletter.com/media/2020/05/25201211/TCL46-18_coronavirus_4x3.jpg)
![COVID-19 vs. community oncology: Flatiron's data provides first damage assessment](https://cdn.cancerletter.com/media/2020/05/25201211/TCL46-18_coronavirus_4x3.jpg)
Cover Story
COVID-19 & CancerFree
Community oncology practices in the United States are reeling from a sharp decrease in business—whether you look at new patients, chemotherapy visits, or non-chemo visits—the result of reduced activity and stay-at-home orders across the country to mitigate the spread of SARS-CoV-2.
COVID-19 Updates
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- What are you reading in 2023?
- U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access - Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence